Relamorelin
- Generic Name
- Relamorelin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C43H50N8O5S
- CAS Number
- 661472-41-9
- Unique Ingredient Identifier
- BIW199E18V
- Background
Relamorelin has been investigated for the treatment and basic science of Gastroparesis, Gastric Motility, Diabetes Mellitus, Parkinson's Disease, and Chronic Constipation, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Gastroparesis for the Nongastroenterologist (Part II)
Gastroparesis diagnosis requires symptoms, exclusion of mechanical obstruction, and evidence of delayed gastric emptying. Gold-standard tests include gastric emptying scintigraphy and the stable isotope gastric-emptying breath test. Management strategies include optimizing nutrition, prokinetic medications, antiemetics, neuromodulators, and nonpharmacologic therapies like gastric electrical stimulation and acupuncture. Surgical options include pyloroplasty and G-POEM for refractory cases.
Gastroparesis Drugs Market to Grow by USD 1.42 Billion from 2024-2028, Driven by Rising ...
Global gastroparesis drugs market to grow by USD 1.42 billion from 2024-2028, driven by rising diabetes prevalence and emerging market opportunities, despite stringent regulatory challenges. Key players include Abbott Laboratories, AbbVie Inc., and others.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath